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Background: Rapid immunochromatographic tests can detect disease markers in 10–15 minutes, 
which facilitates clinical diagnosis and treatment programs. However, most immunochromato-
graphic tests employ gold nanoparticles as reporters, and these have only moderate sensitivity 
and act as qualitative methods for analyzing high biomarker concentrations.
Methods: In this study, we introduce quantum dots (QDs) as fluorescent probes and immu-
nochromatographic strips to develop quantitative fluorescence point-of-care tests (QF-POCT) 
to analyze C-reactive protein (CRP) levels. Goat anti-rabbit IgG and rabbit IgG were used as 
control antibodies, and mouse monoclonal CRP antibody pairs were used for disease marker 
detection. One monoclonal CRP antibody was conjugated with QDs and served as a signal anti-
body, and the other monoclonal CRP antibody was dispensed onto the nitrocellulose membrane 
and served as a capturing antibody. In the presence of CRP, the fluorescence intensity of the 
monoclonal antibody-CRP-monoclonal antibody sandwich complex captured on the nitrocel-
lulose membrane was determined using the fluorescence strip reader.
Results: QF-POCT assays could quantitatively analyze the concentration of CRP in 15 minutes 
had a detection limit of 0.25 mg/L, and had a wide detection linearity range (0.5–300 mg/L). 
The intra-assay and interassay coefficients of variation were 8.95% and 9.86% at 0.5 mg/L, 
6.47% and 8.66% at 10 mg/L, and 6.81% and 9.10% at 60 mg/L, respectively. In a comparison 
between clinical samples, the results of this QD-based assay of CRP levels were significantly 
correlated with those of an Immulite 2000 assay (R=0.993, P0.001).
Conclusion: Our results demonstrated that the QD-based immunochromatographic test is a 
rapid, sensitive, accurate, and quantitative method for the detection of disease biomarkers.
Keywords: C-reactive protein, immunochromatographic test, quantum dots, fluorescence 
point-of-care test
Introduction
The rapid and accurate detection of biomarkers, such as antigens and proteins, in body 
fluids is very important for clinical diagnosis and treatment programs.1–3 Immunological 
detection technology has improved rapidly in the past few decades, and a number of 
immunoassays are widely used in medicine, including radioimmunoassays, enzyme-
linked immunosorbent assays, fluorescence immunoassays, immunoturbidimetric 
assays, and chemiluminescence immunoassays.4–6 However, most of these techniques 
require expensive instrumentation and an inflexible set of reagents.
Rapid immunochromatographic tests were developed in the 1980s, where clini-
cal specimens are applied to a lateral flow strip containing antibodies against target 
antigens, and the presence or absence of the antigen is indicated by a color change on 
the test strip. These tests are simple to use, provide rapid results, and are referred to as 
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point-of-care tests (POCTs).7 Most immunochromatographic 
tests use gold nanoparticles as reporters and can only provide 
qualitative results, but have good specificity and moderate 
sensitivity, and are generally used for analyzing moderate or 
high concentrations of analytes.8,9 A new fluorescence immu-
nochromatographic assay has been developed that consists 
of an immunochromatographic strip and a laser fluorescence 
scanner to provide quantitative results.10 This assay employs 
organic fluorescent dyes, which have intrinsic limitations 
such as photobleaching, limiting its further applications.
Quantum dots (QDs) are semiconductors with optical char-
acteristics that are closely related to the size and shape of the 
individual crystals. They have unique spectral properties such 
as broad excitation, narrow emission ranges, large absorption 
coefficients, strong emission intensity, size-tunable fluores-
cence emission, and excellent stability against photobleaching 
when compared with organic fluorescent dyes.11,12 QDs can be 
used for molecular labeling, cell, in vivo and in vitro imaging, 
and clinical laboratory diagnostics. QDs can also be employed 
as reporters in fluorescence immunochromatographic assays 
owing to their favorable optical properties. Li et al13 introduced 
QDs as fluorescent probes for immunochromatographic tests 
that can quantitatively detect nitrated ceruloplasmin. Yang 
et al14 developed a QD-based immunochromatography test 
for the detection of alpha fetoprotein.
C-reactive protein (CRP) is an acute-phase reactant that 
is synthesized by the liver and is used as a marker of inflam-
mation. The serum CRP concentration can increase by up to 
1,000-fold after infection, trauma, surgery, and other acute 
inflammatory events.15,16 Chronic inflammation is an impor-
tant component in the development and progression of athero-
sclerosis, and increased serum CRP concentrations have been 
demonstrated to be independent predictors of future vascular 
events.17–19 However, the prospect of using CRP as a predic-
tor of future vascular events requires high-sensitivity CRP 
methods. New-generation automated immunoturbidimetric 
and immunoluminometric assays have been developed and are 
commercially available.20,21 These new assays have improved 
the sensitivity and precision for low levels of CRP.22
In the present work, we introduce QDs as fluorescent 
probes and developed a fluorescence POCT assay (QF-POCT)   
that can rapidly, sensitively, and quantitatively analyze levels 
of CRP and high-sensitivity CRP.
Materials and methods
Materials
Goat anti-rabbit IgG and rabbit IgG were purchased from 
Abcam (Boston, MA, USA). Mouse monoclonal CRP anti-
body pairs, and CRP-free serum were obtained from HyTest 
(EuroCity, Finland). Standard human CRP was obtained 
from Sigma (Cambridge, MA, USA). QD-605 nanocrys-
tals, QD-labeled goat-anti-rabbit antibody, succinimidyl 
trans-4-(N-maleimidylmethyl) cyclohexane-1-carboxylate 
(SMCC) stock solution, dithiothreitol stock solution, 
phosphate-buffered saline (0.01 M), bovine serum albumin, 
β-mercaptoethanol, Superdex 200 gel, and Tween-20 were 
obtained from JiaYuan QDs (Wuhan, People’s Republic of 
China). Absorbent pads, sample application pads, conjuga-
tion pads, backing cards, and nitrocellulose membranes were 
purchased from Millipore (Bedford, MA, USA).
A BioJet Quanti 3000 dispenser, LM5000 batch laminating 
system, and CM4000 guillotine cutting system were obtained 
from Biodot Ltd (Irvine, CA, USA). The portable fluorescence 
strip reader ESEQuant lateral flow system was purchased from 
Qiagen (Irvine, CA, USA). An Immulite 2000 immunoassay 
system was obtained from Siemens (Munich, Germany).
Preparation of QD/anti-crP conjugate
The QD/anti-CRP conjugate was prepared according to the 
protocol of the QD conjugation kit supplied by the manufac-
turer (JiaYuan QDs). Briefly, 100 µL of QD-605 nanocrystals 
were first activated with 10 µL of 10 mM SMCC at 25°C 
for 60 minutes. The mixture was then subjected to a NAP-5 
desalting column with the exchange buffer provided with 
the conjugation kit as the elution solvent. The colored eluate 
(~500 µL) was collected. At 25°C, 300 µL of anti-CRP with 
a concentration of 1 mg/mL was reduced with 20 mM dithio-
threitol for 30 minutes. The resulting mixture was purified with 
a NAP-5 desalting column. The above two purified collections 
were mixed and allowed to react at 25°C for one hour to form 
the conjugation complex. Following the addition of 10 µL of 
β-mercaptoethanol, the conjugation reaction was quenched. 
The quenched reaction mixture was then concentrated to 20 µL   
using an ultrafiltration device run at 7,000 rpm for 10–15 minutes   
on a centrifuge. Superdex 200 gel was slowly packed into 
the column. The concentrated conjugation mixture was then 
pipetted into the size-exclusion column to purify the conjugated 
biocomplex. During the gravity elution, the first ten drops of 
colored conjugate were collected and diluted to 1 µM.
Fabrication of QD-based fluorescence 
immunochromatographic assay strips
Preparation of fluorescence immunochromatographic 
solution
The fluorescence immunochromatographic was prepared by 
diluting QD/anti-CRP conjugate and QD-labeled goat-anti-
rabbit antibody with 10 mM phosphate-buffered saline and 
was then stored at 4°C until further use.International Journal of Nanomedicine 2014:9 submit your manuscript | www.dovepress.com
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Preparation of sample application pads
The sample application pads were saturated with 10 mM 
phosphate-buffered saline (pH 7.4) containing 2.0% sucrose, 
2.0% bovine serum albumin, and 0.05% Tween-20 for 
15 minutes. They were then dried at room temperature for 
24 hours. The pads were cut into 320×21 mm pieces and 
stored at room temperature.
Preparation of capturing antibody and control 
antibody
The other mouse monoclonal CRP antibody and rabbit IgG 
were diluted with 10 mM phosphate-buffered saline (pH 7.4) to 
2 mg/mL and 0.5 mg/mL as the capturing antibody and control 
antibody, respectively. The capture antibody (test line) and 
control antibody (control line) were dispensed onto the nitro-
cellulose membrane using a BioJet Quanti 3000 dispenser.
assembly
Absorbent pads, sample application pads, and nitrocellulose 
membranes were affixed on a 300×60 mm backing card, 
which was then cut into 4×60 mm strips and stored.
sample assay procedure
First, 10 µL samples (standard samples or clinical serum) 
were added to the fluorescence immunochromatographic 
solution and mixed. Next, 75 µL mixed solution was applied 
to the sample pad for the reaction. After 6 minutes, the test 
strip was inserted into the portable fluorescence strip reader, 
the fluorescence intensity was estimated from QDs on the 
test line, control line, and baseline, and the fluorescence strip 
reader quantified the results. A schematic illustration of the 
QD-POCT assay procedure is shown in Figure 1A–E.
Method comparison
The samples for the calibration curve of the fluorescence 
POCT assay system were diluted with the standard human 
CRP solution. The limit of detection of the method was 
assessed by analyzing a zero calibrator 20 times and calcu-
lating the 2 SD (standard deviation) limit. Three different 
calibrator samples were used for the studies of precision. 
Each sample was run in duplicate on five different days, with 
ten runs per day, and the total imprecision was calculated.
To compare the assay systems, serum samples were 
obtained from patients at the First Affiliated Hospital of 
Yangtze University, People’s Republic of China, and stored 
at -80°C. They were collected from adult females and males 
aged 21–83 years. All participants provided signed informed 
consent forms, and the study was approved by the ethics com-
mittee of the First Affiliated Hospital of Yangtze University. 
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Figure 1 schematic illustration of the QD-POcT assay procedure.
Notes: ( A)  Add  samples  to  the  fluorescence  immunochromatographic  solution 
and mix. (B) Mixed samples are applied to sample pads. (C) samples migrate along 
the porous membrane by capillary action. (D) crPs were captured by the other 
monoclonal antibodies (ab2) to form (QD) ab1 – ag – ab2 complexes on the test 
line; QD-labeled goat-anti-rabbit abs were captured by rabbit Igg on the control line. 
(E) The fluorescence intensity is detected using a portable fluorescence strip reader. 
Abbreviations: crP, c-reactive protein; Igg, immunoglobulin g; ab, antibody; 
QD, quantum dot; POCT, fluorescence point-of-care test.
The serum sample from each individual was run using 
Immulite 2000 and a fluorescence strip reader, and the CRP 
results were compared.
Results and discussion
Fluorescence imaging and raw readout 
values of the QD-POcT assay
Five different concentrations (0.5, 3, 20, 100, and 200 mg/L) 
of the human CRP standard samples were measured using 
the QF-POCT assay system. The fluorescent band could 
clearly be observed by ultraviolet excitation. The changes in 
fluorescent intensity of the test lines were associated with the 
concentration of CRP; in contrast, the fluorescence intensity 
of the control lines remained the same regardless of CRP 
concentration (Figure 2A–E). The fluorescence intensity 
readout curves of the portable fluorescence strip reader are 
shown in Figure 3. Supplementary Figure 1A–E shows the International Journal of Nanomedicine 2014:9 submit your manuscript | www.dovepress.com
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raw fluorescence intensity readout curves of the QD-POCT 
strips using portable fluorescence strip readers.
calibration curves and linearity  
of analytical results
We estimated the calibration curve with six different con-
centrations of standard CRP, from 0.5 to 300 mg/L, diluted 
in CRP-free serum. The calibration curve was obtained from 
log(T – B/C – B) (FL intensity of test lines – baseline/FL 
intensity of control lines – baseline) and logC (CRP concen-
tration, mg/L) in the calibration samples. The log(T – B/C – B) 
values were plotted against logC. A reliable correlation coef-
ficient (R2) was observed (R2 =0.9986), and a good linearity 
was displayed in the range of 0.5–300 mg/L (Figure 4).
limit of detection
The limit of detection for each method was assessed by analyz-
ing a zero calibrator 20 times. The mean value of T/C +2 SD 
was used for the calibration curve, and the lowest detection 
limit was observed for a concentration of 0.25 mg/L.
Figure 4 calibration curve was obtained from log(T – B/c – B) (y axis) and logc 
(x axis) for calibration samples ranging from 0.5 to 300 mg/l. 
Notes:  T  indicates  Fl  intensity  of  test  lines;  B  indicates  baseline;  c  indicates 
c-reactive protein concentration, mg/l.
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Figure 2 Fluorescence imaging of QD-POcT strips for concentrations of (A) 0.5 mg/l, 
(B) 3 mg/l, (C) 20 mg/l, (D) 100 mg/l, and (E) 200 mg/l c-reactive protein. 
Abbreviations: QD, quantum dot; POCT, fluorescence point-of-care test.
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Figure 3 Fluorescence intensity readout curve of QD-POcT strips using portable 
fluorescence strip readers for concentrations of 0.5 mg/L, 3 mg/L, 20 mg/L, 100 mg/L, 
and 200 mg/l c-reactive protein. 
Abbreviations: QD, quantum dot; POCT, fluorescence point-of-care test.
Imprecision and accuracy
We also evaluated the imprecision of the intraday (within 
day) and interday (between day) assays to determine the accu-
racy of the QF-POCT test. Duplicate tests were performed for 
low (0.5 mg/L), medium (10 mg/L), and high concentrations 
(60 mg/L) of human CRP standard samples. For each sample, 
the tests were repeated ten times per day for the intra-assay 
analysis, and performed on five sequential days with ten 
replicates for the interassay analysis. The intra-assay and 
interassay coefficients of variation in the QF-POCT assay 
were 8.95% and 9.86% at 0.5 mg/L, 6.47% and 8.66% at 
10 mg/L, and 6.81% and 9.10% at 60 mg/L, respectively.
Recovery experiments were performed to assess the accu-
racy of the QF-POCT assay. The serum samples were spiked 
with three different concentrations of human CRP standard 
samples (2.89, 8.59, and 18.5 mg/L) for analysis. All of the 
recovery rates were within the range of 98.5%–104.6% and 
the average recovery rate was 101.3% (Table 1).
clinical sample comparison
For the comparison between methods, 160 patient serum sam-
ples were analyzed by the automated assay (Immulite 2000)   
Table 1 recovery experiments using the QF-POcT assay system
Original sample  
concentration  
(mg/L)
Added  
concentration  
(mg/L)
Recovered  
concentration  
(mg/L)
Recovery  
(%)
Average  
recovery   
(%)
0.89 2.89 2.85 98.50 101.30
8.59 8.66 100.80
18.5 19.35 104.60
Abbreviations: QD, quantum dot; POCT, fluorescence point-of-care test.International Journal of Nanomedicine 2014:9 submit your manuscript | www.dovepress.com
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and the QF-POCT assay (Figure 5). The CRP values esti-
mated using the new QD-based assay were significantly cor-
related with those using the Immulite 2000 assay (R2 =0.993, 
P0.001). The Immulite 2000 method has been approved by 
the US Food and Drug Administration for clinical use and is 
consistent with other immunoturbidimetric and immunolu-
minometric assays. Thus, these results suggest that the QF-
POCT assay system for CRP levels has a good performance 
compared with other widely used automated assay systems.
Interference experiments
The human standard CRP was diluted to 40 mg/L and various 
interferents (bilirubin, triglycerides, and hemoglobin) were 
added to the fluorescence immunochromatographic solution. 
For each sample, the tests were repeated 20 times. The results 
showed that the QF-POCT assay has good specificity, and the 
interferent did not influence the test results (Table 2).
Conclusion
In summary, we successfully developed a QF-POCT assay 
system based on an immunochromatographic strip and 
fluorescent probe for the rapid, sensitive, and quantita-
tive detection of CRP. This QF-POCT assay system takes 
advantage of the low cost and speed of conventional immu-
nochromatographic strips as well as the high sensitivity 
and photostability of QD-based fluorescent immunoassays. 
This assay system performed well compared with other 
automated assay methods and appeared to be well suited as 
a POCT platform for determination of CRP concentrations in 
clinical samples. The QF-POCT assay system had the lowest 
detection limit at 0.25 mg/L and good linearity in the range 
of 0.5–300 mg/L, indicating that this assay can be used for 
risk assessment of cardiovascular diseases and detection of 
acute inflammatory events.
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Figure S1 Raw fluorescence intensity readout curve of QD-POCT strips using a portable fluorescence strip reader for CRP concentrations of (A) 0.5 mg/l, (B) 3 mg/l, 
(C) 20 mg/l, (D) 100 mg/l, and (E) 200 mg/l. 
Abbreviations: ab, antibody; crP, c-reactive protein.
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